WebPaul is a co-founder and board member of Sage Therapeutics (NASDAQ: SAGE) and a co-founder of Voyager Therapeutics (NASDAQ: VYGR) where he served as President, Chief Executive Officer. Dr. Paul is the former director of the Appel Alzheimer’s Disease Research Institute at Weill Cornell Medical College and is currently a Professor of Psychiatry and … Web15 sep. 2024 · SAGE-718, Sage’s first-in-class NMDA receptor PAM and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease (HD), Parkinson’s disease (PD) and Alzheimer’s disease (AD).
Biography of Jim Doherty - The Official Board
WebJim Doherty Chief Development Officer at SAGE Therapeutics Cambridge, Massachusetts, United States 1K followers 500+ connections Join to view profile SAGE … WebJim Doherty Senior Vice President, Research at SAGE Therapeutics Location: Cambridge, Massachusetts Add to My Lists more ClaimEmbed Export James Doherty … patrick lassalle
Sage Therapeutics Announces Presentation of Promising Results …
Web17 mrt. 2024 · Sage Therapeutics is part of the Manufacturing industry, and located in Massachusetts, United States. Sage Therapeutics Location 215 1st St, Cambridge, Massachusetts, 02142, United States Description Industry Pharmaceuticals Healthcare Discover more about Sage Therapeutics Saritha Talapala Work Experience and Education WebSage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs. … Web24 feb. 2024 · Sage Therapeutics, Inc. ( NASDAQ: SAGE) Q4 2024 Earnings Conference Call February 24, 2024 8:00 AM ET Company Participants Helen Rubinstein - Director, IR Barry Greene - CEO Jim Doherty -... patrick lasserre